Status: RESEARCH / PRE-CAPTURE ONLY
Subject: Theranos — technology representations, clinical-laboratory regulation, investor/patient fraud proceedings, and defendant-specific adjudication
Scope: source inventory, authority/posture, record-contradiction map, provisional five-claim matrix, capture hazards, reverse-source candidates
Explicit non-claims: This dossier creates no CaptureReceipt, SourceEdition, SRS receipt, custody, admission, final standing, article prose, or canonical Counterpedia identity.

A. SUBJECT / DISAMBIGUATION

Common name

Theranos scandal

Exact scope

Theranos, Inc.'s blood-testing business and technology claims, especially the 2013–2016 retail-testing period; regulatory findings concerning its clinical laboratory; civil securities enforcement; federal criminal prosecutions of Elizabeth Holmes and Ramesh "Sunny" Balwani; the different verdicts returned by separate juries; sentencing/restitution; and appellate review.

This dossier is not a biography of Elizabeth Holmes, a complete corporate history of Theranos, or a general page about medical-device regulation.

Important names / aliases

• Theranos, Inc.

• Elizabeth A. Holmes

• Ramesh "Sunny" Balwani

• Edison

• Edison 3.5

• Theranos Proprietary System / TPS

• Theranos Sample Processing Unit / TSPU

• miniLab / minilab

• nanotainer

• Walgreens Wellness Centers

• CLIA

• CMS Report

• CLIA Number 05D2025714

• SEC v. Elizabeth Holmes, et al., No. 5:18-cv-01602

• SEC v. Ramesh "Sunny" Balwani, No. 5:18-cv-01603

• United States v. Elizabeth A. Holmes, et al., No. 5:18-cr-00258-EJD

• Ninth Circuit Nos. 22-10312, 22-10338, 23-1040, 23-1167, 23-1166

• Supreme Court No. 25-1330 (Balwani petition pending as of 2026-08-09)

Naming / equivalence traps

1. "Theranos test" is not one technological object. Patient samples were processed on Theranos-developed Edison devices, modified third-party commercial analyzers, and unmodified third-party analyzers. The miniLab was a separate development-stage system.

2. "Fingerstick testing" does not imply "tested on a Theranos proprietary analyzer." A fingerstick sample could be collected in a Theranos nanotainer and then run on an Edison or modified third-party machine.

3. A published testing menu is not a device-capability list. Theranos advertised/offered a broad test menu, while the Ninth Circuit record says only twelve assays were ever run on the Edison.

4. FDA clearance of one assay is not FDA validation of the whole platform. FDA's K143236 record shows a Theranos HSV-1 IgG assay received a 510(k) substantially-equivalent decision; it does not establish that the Edison could accurately perform the entire advertised menu.

5. SEC complaint ≠ SEC adjudicated merits finding. Holmes and Theranos settled SEC charges without admitting or denying the allegations.

6. Criminal indictment ≠ conviction.

7. Holmes verdict ≠ Balwani verdict. The two defendants were tried separately and juries reached materially different patient-fraud outcomes.

8. Acquittal ≠ affirmative factual finding that patient tests were accurate or that no patient was harmed.

9. CMS regulatory "immediate jeopardy" finding ≠ criminal fraud verdict.

10. Sentencing narrative / government characterization of trial evidence ≠ jury finding on every described event.

11. Court-hosted trial exhibit ≠ judicial finding. A Theranos document remains a Theranos-authored document even when preserved on cand.uscourts.gov.

Temporal bounds

Primary demo period: 2010–2026, with emphasis on:

• 2013–2015 retail testing / fundraising;

• 2015–2016 CMS/FDA regulatory period;

• 2018 SEC and criminal charging;

• 2021–2022 trials and verdicts;

• 2022 sentencing;

• 2025 Ninth Circuit opinion and amended opinion;

• 2026 pending Supreme Court petition by Balwani.

Why this is fertile for Counterpedia

Theranos is a near-perfect test of adjudicative posture discipline.

A conventional summary easily compresses all of the following into "Theranos was fraud":

• a company claim;

• an internal or first-party document;

• an SEC allegation;

• an SEC settlement without admission;

• a CMS regulatory deficiency finding;

• a criminal indictment;

• trial evidence;

• a guilty verdict;

• an acquittal;

• a dismissed count;

• a hung count;

• a sentence;

• an appellate affirmance;

• a still-pending certiorari petition.

Counterpedia should make those objects visually and graphically impossible to confuse.

B. SOURCE INVENTORY

TH-S01 — SEC civil complaint against Holmes and Theranos

Exact title: Complaint — Securities and Exchange Commission v. Elizabeth Holmes and Theranos, Inc.
Issuer: U.S. Securities and Exchange Commission
Filed: 2018-03-14
Case: 5:18-cv-01602
Exact locator:
https://www.sec.gov/files/litigation/complaints/2018/comp-pr2018-41-theranos-holmes.pdf

Format: PDF, 24 pages
Authority / posture: Federal civil enforcement complaint. Its factual assertions are SEC allegations at filing, not adjudicated findings merely because the SEC authored them.

May support

• exact content of SEC allegations;

• allegation that >$700 million was raised from late 2013–2015;

• allegation that investors were misled about technology, business relationships, DoD use, FDA status, financials, demonstrations;

• allegation that Theranos' proprietary analyzer performed about 12 tests of >200 on the published patient menu and third-party analyzers performed the remainder.

Cannot establish alone

• that Holmes admitted those allegations;

• that a court adjudicated every allegation;

• patient-level criminal guilt.

Conflicts / qualifies

• paired with TH-S02 settlement posture;

• later criminal verdicts establish some fraud propositions through a different proceeding and burden of proof, but they do not retroactively convert every SEC allegation into a jury finding.

Captureability: HIGH
Hazards: none significant; preserve exact filed PDF bytes and filing date.
Priority: P0

TH-S02 — SEC charging / settlement announcement

Exact title: Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud
Issuer: SEC
Date: 2018-03-14
Exact locator:
https://www.sec.gov/newsroom/press-releases/2018-41

Format: HTML
Authority / posture: SEC enforcement announcement summarizing complaints and Holmes/Theranos settlement terms.

May support

• Holmes/Theranos agreed to settle;

• $500,000 penalty, 10-year public-company officer/director bar, share/voting-control terms;

• explicit posture sentence: Theranos and Holmes neither admitted nor denied complaint allegations.

Critical qualification A settlement with sanctions is not an admission of the underlying complaint allegations unless the settlement says so. Here the SEC expressly says the opposite.

Captureability: HIGH
Hazards: live agency HTML can change cosmetically; capture exact bytes and retrieved date.
Priority: P0

TH-S03 — SEC civil complaint against Balwani

Exact title: Complaint — Securities and Exchange Commission v. Ramesh "Sunny" Balwani
Issuer: SEC
Filed: 2018-03-14
Case: 5:18-cv-01603
Exact locator:
https://www.sec.gov/files/litigation/complaints/2018/comp-pr2018-41-balwani.pdf

Format: PDF, 23 pages
Authority / posture: SEC civil complaint against Balwani; allegations, not findings at filing.

May support

• exact allegations separately made against Balwani;

• the SEC's pleaded technology/investor representations;

• defendant-specific civil posture.

Cannot establish

• criminal guilt;

• that every allegation was later adjudicated.

Captureability: HIGH
Priority: P1

TH-S04 — DOJ criminal case hub and indictment record

Exact title: U.S. v. Elizabeth Holmes, et al.
Issuer: U.S. Attorney's Office, Northern District of California
Exact locator:
https://www.justice.gov/usao-ndca/us-v-elizabeth-holmes-et-al

Initial indictment PDF linked by DOJ:
https://www.justice.gov/d9/pages/attachments/2019/02/26/holmes_and_balwani_indictment_0.pdf

Initial indictment date: 2018-06-14
Operative indictment lineage: superseded 2020-07-14 and again 2020-07-28; CAP1 should resolve and capture the exact operative Third Superseding Indictment from the federal court docket as a separate artifact.

Format: HTML hub + PDF(s)
Authority / posture: indictment allegations / criminal procedural record. At charge stage, allegations are not guilt.

May support

• exact count structure and charged investor/patient schemes;

• procedural lineage;

• government allegations and later links to verdict/sentencing materials.

Cannot establish

• guilt merely from indictment.

Captureability: HIGH for hub and initial indictment; MEDIUM for exact operative indictment until direct court artifact is resolved.
Hazard: the DOJ hub's linked PDF is the 2018 initial indictment, not necessarily the operative 2020 charging instrument used at trial. Never silently substitute one for the other.
Priority: P0

TH-S05 — Holmes criminal verdict announcement

Exact title: Theranos Founder Elizabeth Holmes Found Guilty Of Investor Fraud
Issuer: U.S. Attorney's Office, Northern District of California
Date: 2022-01-04 (verdict returned 2022-01-03)
Exact locator:
https://www.justice.gov/usao-ndca/pr/theranos-founder-elizabeth-holmes-found-guilty-investor-fraud

Format: HTML
Authority / posture: official government report of jury verdict; the verdict itself is an adjudicative disposition.

Exact procedural pattern

• GUILTY: investor-fraud conspiracy + 3 substantive investor wire-fraud counts;

• ACQUITTED: patient-fraud conspiracy + 3 other wire-fraud counts;

• DISMISSED DURING TRIAL: one patient-related wire-fraud count;

• NO UNANIMOUS VERDICT: 3 investor-fraud counts.

May support

• what Holmes was and was not convicted of.

Cannot establish

• that an acquitted patient-fraud charge proves all patient tests were accurate;

• that Balwani received the same verdict.

Captureability: HIGH
Priority: P0

TH-S06 — Balwani criminal verdict announcement

Exact title: Theranos Chief Operating Officer Ramesh “Sunny” Balwani Found Guilty Of Conspiracy, Wire Fraud
Issuer: U.S. Attorney's Office, Northern District of California
Date: 2022-07-07
Exact locator:
https://www.justice.gov/usao-ndca/pr/theranos-chief-operating-officer-ramesh-sunny-balwani-found-guilty-conspiracy-wire

Format: HTML
Authority / posture: official government report of separate jury verdict.

Exact procedural pattern

• GUILTY on all counts: 2 conspiracy + 10 wire fraud;

• included investor-fraud and patient-fraud conspiracy;

• included 6 investor wire-fraud counts and 4 patient-related wire-fraud counts.

Counterpedia value The same corporate story produced a materially different defendant-specific adjudication:

• Holmes: investor convictions, patient acquittals;

• Balwani: investor and patient convictions.

Captureability: HIGH
Priority: P0

TH-S07 — Holmes sentencing record / DOJ announcement

Exact title: Elizabeth Holmes Sentenced To More Than 11 Years For Defrauding Theranos Investors Of Hundreds Of Millions
Issuer: U.S. Attorney's Office, Northern District of California
Date: 2022-11-18
Exact locator:
https://www.justice.gov/usao-ndca/pr/elizabeth-holmes-sentenced-more-11-years-defrauding-theranos-investors-hundreds

Format: HTML
Authority / posture: government sentencing announcement; sentence is adjudicative, narrative descriptions of trial evidence remain government descriptions unless bound to court findings/transcript/exhibits.

May support

• 135-month sentence;

• conviction recap;

• government's characterization of trial evidence;

• Theranos eventually voided tests run on its analyzer (useful but should be anchored to underlying exhibit/court record if promoted beyond attributed government narrative).

Important qualification The sentencing page discusses patient test problems while also explicitly recounting Holmes's acquittal on patient-fraud counts. Those are not contradictory because evidentiary facts and criminal-count dispositions answer different questions.

Captureability: HIGH
Priority: P1

TH-S08 — Balwani sentencing record / DOJ announcement

Exact title: Theranos President Sentenced To More Than 12 Years For Fraud That Jeopardized Patient Health And Bilked Investors Of Millions
Issuer: U.S. Attorney's Office, Northern District of California
Date: 2022-12-07
Exact locator:
https://www.justice.gov/usao-ndca/pr/theranos-president-sentenced-more-12-years-fraud-jeopardized-patient-health-and-bilked

Format: HTML
Authority / posture: government sentencing announcement following all-counts guilty verdict.

May support

• 155-month sentence;

• patient/investor conviction scope;

• selected trial-evidence descriptions.

Captureability: HIGH
Priority: P1

TH-S09 — Ninth Circuit amended opinion

Exact title / caption: United States of America v. Elizabeth A. Holmes; United States of America v. Ramesh Sunny Balwani — Order and Amended Opinion
Court: U.S. Court of Appeals for the Ninth Circuit
Filed: 2025-02-24
Amended: 2025-12-22
Exact current locator:
https://cdn.ca9.uscourts.gov/datastore/opinions/2025/12/22/22-10312.pdf

Earlier opinion locator / edition:
https://cdn.ca9.uscourts.gov/datastore/opinions/2025/02/24/22-10312.pdf

Format: PDF, current amended opinion 55 pages
Authority / posture: published federal appellate judicial opinion.

May support

• affirmance of Holmes's and Balwani's convictions and sentences;

• affirmance of district court $452 million restitution order;

• appellate treatment of CMS Report admissibility, witness testimony, voided patient tests, loss/restitution;

• judicial factual-background synthesis of trial record:

  • Edison was the only Theranos-developed device ever used to test patient samples;

  • Theranos developed 300 small-sample assays, but only 12 were ever run on Edison;

  • other general-chemistry tests were run on third-party machines;

  • CMS inspection identified immediate-jeopardy/quality-control problems;

  • investor demonstrations could use null protocols while samples were tested elsewhere;

  • military clinical deployment claims did not match the trial evidence.

Important qualification Court-staff summary is explicitly not part of the court's opinion; claim binding should prefer the opinion body where available.

Source-version value Same appellate case/opinion identity, later amended bytes. Capture both versions if possible.

Captureability: HIGH
Priority: P0

TH-S10 — Balwani Supreme Court certiorari docket

Exact title: Ramesh Sunny Balwani, Petitioner v. United States
Court: Supreme Court of the United States
Docket: No. 25-1330
Docketed: 2026-06-01
Exact locator:
https://www.supremecourt.gov/docket/docketfiles/html/public/25-1330.html

Current procedural status as of 2026-08-09

• certiorari petition filed 2026-05-21;

• United States waived response 2026-06-09;

• distributed 2026-06-17 for Conference of 2026-09-28.

Authority / posture: official Supreme Court procedural docket. A pending cert petition does not vacate the Ninth Circuit judgment and is not a merits ruling by the Supreme Court.

Counterpedia value Demonstrates that "affirmed on appeal" and "all appellate avenues exhausted / Supreme Court finally resolved" are not synonyms.

Captureability: HIGH
Priority: P1

TH-S11 — CMS Condition-Level Deficiencies / Immediate Jeopardy record

Exact title identified from the document: CONDITION LEVEL DEFICIENCIES — IMMEDIATE JEOPARDY
Issuer: Centers for Medicare & Medicaid Services, Western Division of Survey and Certification, San Francisco Regional Office
Date: 2016-01-25
Addressee: Sunil Dhawan, M.D., Director, Theranos, Inc.
CLIA number: 05D2025714

Primary-origin locator status: UNRESOLVED IN CURRENT RECON.
The exact CMS-origin PDF was not found on a currently indexed cms.gov page.

Institutional corroboration

• Ninth Circuit amended opinion describes the CMS Report and immediate-jeopardy finding.

• Later CMS July 7, 2016 sanctions letter recites the Jan. 25 finding.

• Public non-origin copies exist, but they must not be silently represented as CMS-origin capture.

Known reconnaissance mirror — DO NOT treat as origin:
The Jan. 25 PDF has circulated through historical media/archive copies; CAP1 should locate an official court-filed copy, CMS archival copy, or authenticated government exhibit before admission-quality use.

Authority / posture: CMS regulatory inspection/finding.

May support once authentic bytes are acquired

• condition-level deficiencies;

• "immediate jeopardy to patient health and safety" regulatory finding;

• exact cited CLIA deficiencies.

Cannot establish

• Holmes's criminal guilt;

• that every Theranos test was inaccurate;

• precise error rate across all tests.

Captureability: BLOCKED / PRIMARY BYTES NOT YET LOCATED
Priority: P0 research need / CAP gate

TH-S12 — CMS July 7, 2016 Imposition of Sanctions

Exact title / subject: IMPOSITION OF SANCTIONS
Issuer: CMS Western Division of Survey and Certification
Date: 2016-07-07

Primary-origin locator status: UNRESOLVED IN CURRENT RECON.

Document identity is well-established The letter states CMS determined that Theranos:

• was not in compliance with CLIA Condition-level requirements;

• had not removed the immediate-jeopardy finding;

• would face revocation/limitation of CLIA certificate, civil money penalty, directed correction, and Medicare/Medicaid consequences.

Known non-origin transcription/mirror: Wikisource hosts a validated transcription of a public copy. That is reconnaissance only, not a substitute for origin/government/court bytes.

May support once authentic bytes captured

• actual regulatory sanctions posture;

• distinction between Jan. 25 deficiency finding, Mar. 18 proposed sanctions, and Jul. 7 imposed sanctions.

Captureability: PRIMARY LOCATOR UNRESOLVED
Priority: P1 / important regulatory chronology

TH-S13 — Federal court-hosted Theranos testing menu

Exact title / filename: Trial Exh. 3741a Theranos Testing Menu.pdf
Host: U.S. District Court, Northern District of California public trial-exhibit repository
Exact locator:
https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%203741a/Trial%20Exh.%203741a%20Theranos%20Testing%20Menu.pdf

Directory locator:
https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%203741a/

Format: PDF, 7 pages, tabular menu
Authorship / posture: Theranos testing-menu document admitted/published as a trial exhibit. It remains a Theranos-authored first-party artifact, not a judicial finding.

May support

• the breadth and pricing of a published/offered testing menu;

• exact advertised tests.

Cannot support

• that every listed test ran on Edison;

• accuracy of every listed test;

• regulator approval of the menu.

Captureability: HIGH
Hazards: table/image extraction can be noisy; use artifact-tied page/table anchors, not OCR text alone.
Priority: P0 for the technology/menu denominator demo.

TH-S14 — Federal court-hosted Theranos cash-balance spreadsheet

Exact filename: Trial Exh. 5172 Theranos Cash Balance.xlsx
Host: U.S. District Court, Northern District of California
Directory locator:
https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%205172/

Format: XLSX, 333,097 bytes according to court directory
Authorship / posture: Theranos business record admitted/published as trial exhibit, not a court finding.

May support

• exact first-party financial data represented in the spreadsheet, after workbook inspection;

• comparison against investor financial representations only after scope/date/accounting fields are reconciled.

Captureability: MEDIUM-HIGH
Hazards

• child download should be resolved and hashed by CAP1;

• spreadsheet semantics must be inspected without flattening cells into a single "revenue" number;

• cash balance, revenue, income, and valuation are different measures.

Priority: P2

TH-S15 — FDA 510(k) record for Theranos HSV-1 assay

Exact device name: Theranos Herpes Simplex Virus-1 IgG Assay
Issuer: U.S. Food and Drug Administration
510(k): K143236
Received: 2014-11-12
Decision date: 2015-07-02
Decision: Substantially Equivalent (SESE)
Exact locator:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K143236

Format: official FDA database HTML with linked summary/review materials
Authority / posture: FDA device-specific regulatory decision.

May support

• a specific Theranos assay received a 510(k) substantially-equivalent decision;

• exact device/assay identity and regulatory scope.

Cannot support

• that the entire Theranos platform was FDA-approved;

• that every Theranos test was validated;

• that every Edison assay was reliable;

• broad marketing claims about hundreds of tests.

Why it matters This is an essential corrective to the equally sloppy opposite claim:

"Theranos technology was entirely fake and never had any legitimate regulated assay."

Captureability: HIGH
Priority: P0 because it forces technical scope discipline.

TH-S16 — FDA CLIA-waived record for Theranos anti-HSV-1 assay

Exact document/device: Theranos anti-HSV-1 IgG Assay (Fingerstick Whole Blood Only)
Document: CW150009
Parent: K143236
Effective date: 2015-07-15
Exact locator:
https://www.accessdata.fda.gov/SCRIPTS/CDRH/CFDOCS/CFCLIA/Results.cfm?Analyte_Name=Herpes+simplex+I+and%2For+II+antibodies&Clia_Complexity=waived&SortColumn=dad&san=1

Authority / posture: FDA/CMS CLIA categorization database for a specific assay/use.

May support

• fingerstick whole-blood scope and waived-complexity categorization for this specific assay.

Cannot support

• full-menu fingerstick capability;

• whole-platform validity.

Captureability: HIGH
Priority: P1

TH-S17 — Arizona Attorney General Theranos consent-judgment record

Exact source surface: Past Arizona Settlements and Judgments — Theranos, Inc.
Issuer: Arizona Attorney General's Office
Settlement announced: April 2017
Exact locator:
https://www.azag.gov/consumer/past-settlements

Format: HTML
Authority / posture: state consumer-enforcement settlement/consent judgment summary.

May support

• Theranos agreed to $4.65 million in consumer restitution;

• Arizona described the outcome as a consent judgment and full refunds for Arizonans who purchased Theranos blood tests;

• settlement distribution/closure status.

Cannot establish alone

• a criminal conviction;

• an admission of every alleged consumer-fraud fact unless the underlying consent judgment so states.

Captureability: HIGH for current official summary; underlying signed consent judgment should be separately resolved if available through state records/court.
Priority: P1

TH-S18 — Wikipedia comparison surface — OPTIONAL

Title: Theranos
Issuer/authorship: Wikipedia community
Role: familiar secondary comparison surface only
Locator: https://en.wikipedia.org/wiki/Theranos

Capture rule If used in a demo, pin a specific oldid at capture time. Do not let live article drift silently alter comparison content.

Authority / posture: secondary collaborative narrative; no automatic Counterpedia authority.
Priority: OPTIONAL / comparison only

C. RECORD-CONTRADICTION / QUALIFICATION MAP

C-1 — "Theranos was charged" vs "Theranos/Holmes admitted fraud"

SEC

The SEC filed civil fraud allegations against Holmes, Theranos, and Balwani.

Holmes/Theranos civil disposition

Holmes and Theranos settled. The SEC expressly states they neither admitted nor denied the complaint allegations.

Criminal case

Years later, a criminal jury convicted Holmes of specified investor fraud counts beyond a reasonable doubt.

Counterpedia rule

The later criminal conviction does not rewrite the 2018 civil settlement into an admission that never occurred.

Correct graph:

SEC allegation
→ civil settlement without admit/deny

separately:

DOJ indictment
→ trial evidence
→ Holmes investor-fraud guilty verdict

The objects may concern overlapping conduct, but their postures remain distinct.

C-2 — Holmes verdict vs Balwani verdict

This is the central Theranos contradiction specimen.

Holmes jury

• guilty: investor conspiracy + 3 investor wire-fraud counts;

• acquitted: patient conspiracy + 3 patient-related wire-fraud counts;

• 1 patient count dismissed during trial;

• 3 investor counts hung.

Balwani jury

• guilty on all counts;

• included investor conspiracy and patient conspiracy;

• included investor and patient wire-fraud counts.

Counterpedia rule

Never promote:

"The Theranos defendants were convicted of the same fraud."

Never demote:

"Because Holmes was acquitted on patient counts, no Theranos patient fraud was adjudicated."

Balwani's separate patient-fraud convictions exist and must remain defendant-specific.

C-3 — Patient-test problems vs Holmes's patient-count acquittals

Regulatory/trial/appellate sources describe:

• CMS immediate-jeopardy/quality-control problems;

• quality-control problems on Edison and modified commercial analyzers;

• individual inaccurate-test evidence;

• eventual voiding of tests run on the Theranos analyzer.

Holmes's jury nevertheless acquitted her on the patient-related conspiracy and several individual patient wire-fraud counts.

These propositions are not logically inconsistent.

A criminal acquittal establishes that the government did not obtain a guilty verdict on that charge under the criminal burden and elements. It does not establish:

• every test was accurate;

• no patient received a bad result;

• the CMS findings were false;

• no other individual committed patient fraud.

This is an ideal demonstration of procedural disposition vs underlying factual record.

C-4 — "Theranos testing" denominator problem

The Ninth Circuit opinion says:

• Edison was the only Theranos-developed device ever used to test patient samples;

• 300 small-sample assays were developed during Holmes's time;

• only 12 assays were ever run on Edison;

• other general-chemistry tests were run on third-party machines;

• fingerstick samples could be run on Edison or modified third-party devices.

The court-hosted Theranos Testing Menu lists a far broader catalog of tests.

Therefore:

tests listed/offered
≠ assays developed
≠ assays run on Edison
≠ tests run on third-party instruments
≠ FDA-cleared assays

The numbers can all be true while answering different questions.

C-5 — "The technology was fake" vs specific FDA clearance

FDA's current database shows K143236, the Theranos Herpes Simplex Virus-1 IgG Assay, received a 510(k) substantially-equivalent decision on July 2, 2015. A CLIA database entry also identifies the fingerstick-whole-blood-only assay as waived effective July 15, 2015.

That does not rescue broad Theranos claims about:

• the full menu;

• the miniLab;

• hundreds of assays;

• all tests from a few drops;

• overall lab quality.

But it means this popular formulation is too broad:

"Theranos never developed a single legitimate regulated blood test."

Counterpedia should preserve the strange but important middle state:

One specific assay can have a real regulatory clearance while the broad platform/business representations remain false or misleading in the ways later adjudicated.

C-6 — CMS regulatory finding vs fraud finding

CMS's "immediate jeopardy" finding concerns CLIA laboratory compliance and patient health/safety.

It is not:

• a securities-fraud judgment;

• proof of Holmes's intent;

• proof that every patient test was wrong.

Conversely, Holmes's investor-fraud conviction is not a substitute for CMS technical/regulatory findings.

This is exactly why "official source" cannot be a single authority class.

C-7 — Trial exhibit vs judicial finding

The Theranos Testing Menu is court-hosted because it was a trial exhibit.

Its content can establish:

• what the document says Theranos offered/priced.

It does not become true merely because a federal court hosts it.

The relationship should be:

Court docket/exhibit custody
→ Theranos-authored artifact

not:

Court hosted
→ Court found document's claims true

C-8 — Appellate opinion source-version drift

The Ninth Circuit filed its opinion February 24, 2025 and issued an amended opinion December 22, 2025.

That provides another natural Counterpedia edition demo:

same appellate proceeding/work
→ Feb 2025 opinion artifact
→ Dec 2025 amended opinion artifact

Citations should bind to an exact edition, not merely "the Ninth Circuit opinion."

C-9 — "Affirmed" vs "final beyond further review"

The Ninth Circuit amended opinion affirmed both defendants' convictions/sentences/restitution.

As of August 9, 2026, however, Balwani's Supreme Court certiorari petition, No. 25-1330, is pending and has been distributed for the September 28, 2026 conference.

Therefore:

• "Ninth Circuit affirmed" — documentable;

• "Supreme Court affirmed" — not established;

• "Balwani has no pending petition" — false as of this research date.

This is temporal/procedural truth, not a change in the underlying trial verdict.

D. FIVE-CLAIM DEMONSTRATION MATRIX — PROVISIONAL ONLY

C1 — Observable / concrete event fact

Provisional wording

Theranos publicly launched patient testing in Walgreens stores in the fall of 2013 and then raised investment capital while operating a retail clinical-testing business.

Candidate sources

• TH-S09 Ninth Circuit amended opinion

• TH-S01 SEC complaint

• TH-S13 testing menu

Can establish

• retail-launch chronology;

• fundraising followed public launch;

• Theranos offered a broad testing menu.

Cannot establish

• that the entire menu was performed on Theranos proprietary devices;

• that every retail test was inaccurate;

• fraud by itself.

Likely authority/posture

• judicial factual background + first-party artifact

Qualification "Walgreens offered Theranos tests" must not silently become "Walgreens stores contained fully operational miniLabs performing the whole menu."

Strengthening / reopening Underlying Walgreens/Theranos contract and exact store launch records if page prose needs store counts or exact rollout scope.

C2 — Measurement / structural fact

Provisional wording

The Ninth Circuit's trial-record summary states that Theranos developed about 300 small-sample assays during Holmes's tenure, but only 12 assays were ever run on the Edison; other general-chemistry tests were run on third-party machines.

Candidate sources

• TH-S09

• TH-S13

• TH-S01 / TH-S03

• trial exhibits identifying particular device/test mappings if captured

Can establish

• three distinct denominators: developed assays, Edison assays, broad testing menu;

• existence/use of third-party analyzers.

Cannot establish

• that "300 assays developed" means 300 clinically validated assays;

• that every non-Edison test was deceptive;

• a universal test-error rate.

Likely posture

• judicial factual-record synthesis; underlying exhibits should be bound for stronger device-by-device claims.

Refusal branch

"Theranos advertised 200+ tests, therefore it claimed Edison itself ran every one."

That inference requires exact representation evidence; menu breadth alone is insufficient.

Strengthening Capture investor decks, Walgreens materials, exact test/device mapping records.

C3 — Action / regulatory chronology

Provisional wording

Following a late-2015 unannounced CMS inspection, CMS identified clinical-laboratory deficiencies presenting immediate jeopardy to patient health; Theranos later voided patient sample tests run on its proprietary analyzer.

Candidate sources

• TH-S09 Ninth Circuit amended opinion

• TH-S11 authentic CMS Jan. 25 record once recovered

• TH-S12 authentic CMS Jul. 7 sanctions letter once recovered

• TH-S07 / TH-S08 as attributed DOJ sentencing summaries

Can establish

• inspection/regulatory sequence;

• immediate-jeopardy finding;

• later test-voiding action.

Cannot establish

• that every Theranos test on every device was inaccurate;

• fraud intent merely from regulatory noncompliance;

• the exact scope/date of voiding until underlying notice is captured.

Likely posture

• regulator finding + company corrective action / trial evidence

Capture gate C3 should not be frozen for admission until primary/authenticated CMS bytes are acquired.

C4 — Carefully bounded explanatory / adjudicative proposition

Provisional wording

A federal jury convicted Holmes of conspiring to defraud Theranos investors and of three investor wire-fraud counts; the Ninth Circuit later affirmed her convictions and described the trial record as involving materially misleading representations about Theranos's technology, finances, commercial relationships, military use, third-party analyzers, and pharmaceutical validation.

Candidate sources

• TH-S05

• TH-S09

• underlying verdict form and judgment from CAND/PACER for governed capture

Can establish

• exact Holmes conviction scope;

• appellate affirmance;

• categories of misrepresentation in the criminal case.

Cannot establish

• a Holmes patient-fraud conviction;

• that every Theranos marketing statement was fraudulent;

• that every patient outcome was caused by fraud.

Likely posture

• criminal adjudication, defendant- and count-specific

Qualification If wording says "the jury found X," bind X to the actual verdict/count or trial record; do not attribute every appellate background sentence to the jury.

Strengthening Direct verdict form, judgment, count-specific jury instructions.

C5 — Contested / commonly compressed proposition

Popular formulation

Elizabeth Holmes was convicted of defrauding Theranos patients with fake blood tests.

Located record

• Holmes was charged with patient fraud.

• Her trial included evidence concerning patient testing and accuracy.

• The Holmes jury acquitted her of the patient-fraud conspiracy count and three patient-related wire-fraud counts.

• One additional patient wire-fraud count was dismissed during trial.

• Holmes was convicted on investor-fraud counts.

• A separate Balwani jury later convicted Balwani on both investor and patient fraud counts.

• CMS independently made laboratory-regulatory findings concerning immediate jeopardy and quality-control deficiencies.

What can be established

• Holmes's investor fraud convictions;

• Holmes's patient-count acquittals/dismissal;

• Balwani's patient-fraud convictions;

• independent regulatory/test-quality evidence in its own posture.

What cannot be published at the proposed scope

"Holmes was convicted of patient fraud."

That is contradicted by the criminal verdict record.

Critical Counterpedia qualification Holmes's acquittals also do not justify:

"Theranos patients were never deceived or harmed."

That is a different proposition with different evidence.

Reopening condition For the specific verb "convicted", only a later separate criminal adjudication convicting Holmes of a patient-fraud offense could support that formulation. Additional scientific evidence, complaints, or regulator findings cannot transform an acquittal into a conviction.

For a different formulation such as:

"Theranos produced inaccurate patient results"

the reopening/support condition is different: authenticated regulatory records, test data, patient records, expert analysis, and/or adjudicated findings can support it without pretending Holmes was convicted on those counts.

E. BEST "WHY NOT?" SPECIMEN

Strong popular formulation

"Holmes was convicted for selling fake blood tests to patients."

Why Counterpedia should refuse it

Because the procedural record is unusually precise:

Holmes

Convicted

• investor conspiracy;

• three investor wire-fraud counts.

Acquitted

• patient-fraud conspiracy;

• three patient-related wire-fraud counts.

Dismissed

• another patient-related wire-fraud count.

Hung

• three investor counts.

Balwani

A separate jury later convicted him on both investor and patient fraud counts.

Regulatory record

CMS's laboratory findings and patient-testing evidence exist independently of both verdicts.

Therefore ordinary narrative compression creates two opposite errors:

Overstatement

"Holmes was convicted of patient fraud."

and

False exonerating inference

"Holmes was acquitted on patient counts, therefore patient testing was fine."

Counterpedia should reject both.

Reopening rule

The word convicted is a procedural fact and has a procedural reopening condition.

More evidence about inaccurate tests cannot promote "Holmes was convicted of patient fraud." Only a later criminal conviction on a patient-fraud offense could do that.

That distinction is exactly what a governed knowledge system should enforce.

F. SECONDARY "WHY NOT?" — TECHNOLOGY SCOPE

Strong formulation

"Theranos's technology was completely fake; none of it ever worked or received legitimate regulatory clearance."

Why not

The record supports powerful narrower propositions:

• Edison ran only 12 assays according to the Ninth Circuit's trial-record summary;

• a much broader menu existed;

• many tests were performed on third-party instruments;

• CMS later found serious laboratory deficiencies;

• investor fraud convictions were obtained.

But FDA's official K143236 database record also exists:

• device: Theranos HSV-1 IgG Assay;

• decision: substantially equivalent;

• July 2, 2015;

• related CLIA record identifies fingerstick-whole-blood-only waived use.

So the record itself requires a non-binary technical sentence:

A specific Theranos assay received a real FDA regulatory clearance, while that narrow clearance did not validate the broad platform capabilities Theranos represented to investors and the public.

This is a superb demonstration that one settled scandal can contain both genuine technical/regulatory accomplishment and adjudicated deception without one laundering the other.

G. SOURCE-PAGE / REVERSE-WIKIPEDIA CANDIDATES

1. TH-S09 — Ninth Circuit amended opinion

Why it is ideal

One source connects:

• underlying indictment;

• two separate trials;

• Holmes/Balwani evidence;

• CMS Report;

• device architecture;

• third-party analyzers;

• patient-test voiding;

• restitution;

• appellate holdings.

Reverse traversal

Dec 2025 amended opinion artifact
→ exact appellate holdings
→ Holmes claims
→ Balwani claims
→ CMS evidence
→ trial exhibits
→ prior Feb 2025 opinion edition
→ current certiorari posture

It also demonstrates same judicial work, multiple SourceEditions.

2. TH-S05 + TH-S06 — defendant-specific verdict pair

These should be presented as a paired reverse-source experience.

Holmes verdict → investor convictions
→ patient acquittals
→ dismissed count
→ hung counts

Balwani verdict → investor convictions
→ patient convictions

Then reverse into every Counterpedia claim that depends on each disposition.

This is the cleanest possible demonstration that:

a scandal-level narrative cannot substitute for defendant/count-level adjudication.

3. TH-S13 — Theranos Testing Menu

Why it is ideal

A reader can start on a mundane first-party artifact listing tests and prices.

Reverse traversal can show:

• every test represented in the menu;

• which claims cite menu breadth;

• which device-capability claims cannot cite the menu alone;

• Ninth Circuit 12-Edison-assay finding;

• FDA's one specific cleared assay;

• CMS findings affecting particular assays/devices once exact records are captured.

This turns a simple corporate menu into a graph of advertised scope vs device scope vs regulatory scope.

4. TH-S15 — FDA K143236

This is the unexpected Source Page.

Reverse traversal:

• exact HSV-1 assay clearance;

• its narrow intended/regulatory scope;

• related CLIA waived record;

• claims it supports ("a Theranos assay received 510(k) clearance");

• claims it constrains ("nothing Theranos built ever had regulatory clearance");

• claims it cannot support ("FDA validated Theranos's entire testing platform").

That is the kind of source-level nuance ordinary scandal summaries usually discard.

H. 30–60 SECOND DEMO MOMENT

Start with the familiar sentence:

"Elizabeth Holmes was convicted of defrauding Theranos investors and patients."

Click Why this page?

Counterpedia does not return a generic green "verified."

It expands the procedural graph:

SEC — 2018
civil fraud allegations
→ Holmes/Theranos settled
→ neither admitted nor denied

DOJ — Holmes trial — 2022
investor conspiracy → GUILTY
3 investor wire counts → GUILTY
patient conspiracy → ACQUITTED
3 patient wire counts → ACQUITTED
1 patient count → DISMISSED
3 investor counts → NO UNANIMOUS VERDICT

DOJ — Balwani trial — 2022
investor fraud → GUILTY
patient fraud → GUILTY

CMS — separate authority laboratory deficiencies / immediate jeopardy
→ regulatory finding, not criminal verdict

Then the UI rewrites the sentence to the strongest defensible form:

Holmes was convicted of investor fraud. Balwani was separately convicted of investor and patient fraud. Theranos also faced independent regulatory findings concerning laboratory quality and patient safety.

Then click the second reveal:

"So none of Theranos's technology was real?"

Counterpedia surfaces FDA K143236:

one specific Theranos HSV-1 IgG assay received 510(k) clearance.

And immediately constrains it:

that does not validate the broad platform or hundreds-test narrative.

The product becomes obvious in under a minute: different verbs are different evidence states.

I. CAPTURE PRIORITY

P0 — essential; demo fails without

1. TH-S09 Ninth Circuit Dec. 22, 2025 amended opinion

2. TH-S05 Holmes verdict

3. TH-S06 Balwani verdict

4. TH-S01 SEC Holmes/Theranos complaint

5. TH-S02 SEC settlement announcement / no-admit-no-deny posture

6. TH-S13 court-hosted Theranos Testing Menu

7. TH-S15 FDA K143236 record + linked FDA decision summary

8. TH-S11 authentic CMS Jan. 25, 2016 immediate-jeopardy record — currently a capture blocker until institutional/court bytes are located

P1 — important corroboration / contradiction

1. TH-S04 criminal case hub + exact operative Third Superseding Indictment

2. TH-S03 SEC Balwani complaint

3. TH-S07 Holmes sentencing

4. TH-S08 Balwani sentencing

5. TH-S12 authentic CMS July 7, 2016 sanctions letter

6. TH-S16 FDA/CLIA waived classification record

7. TH-S17 Arizona AG settlement record

8. TH-S10 current Supreme Court Balwani docket

P2

1. TH-S14 Theranos cash-balance spreadsheet

2. direct underlying investor decks, DoD correspondence, pharma-validation reports, Walgreens records as needed for narrower future claims

OPTIONAL

1. TH-S18 Wikipedia comparison edition, pinned by oldid

J. INTEGRITY FLAGS

1. Holmes and Balwani must never share a verdict node

Their proceedings are related but distinct. Every conviction/acquittal edge must name:

• defendant;

• count;

• tribunal/jury;

• disposition;

• date.

2. "Acquitted" is not "factually exonerated on all underlying patient issues"

An acquittal is a disposition on a charged offense under the applicable criminal standard and elements. Patient test evidence and regulatory findings require their own adjudication.

3. SEC settlement has explicit no-admit/no-deny posture

Do not write:

"Holmes admitted the SEC allegations by settling."

The SEC source expressly says Theranos and Holmes neither admitted nor denied them.

4. SEC allegation numbers need posture labels

The SEC complaint's:

• $700M raised;

• ~12 of >200 tests;

• DoD/financial representations

are allegations in that source. Where the Ninth Circuit or verdict record independently establishes overlapping facts, bind the later source separately rather than silently upgrading the complaint.

5. CMS primary bytes are still missing from current recon

This is the biggest corpus-integrity gap.

Current research identified:

• Jan. 25, 2016 CONDITION LEVEL DEFICIENCIES — IMMEDIATE JEOPARDY;

• Mar. 18 proposed sanctions;

• Jul. 7 imposition of sanctions;

but did not locate a current cms.gov origin PDF for those historical records.

Public mirrors/transcriptions are reconnaissance only.

CAP1 must either

• locate CMS archival bytes;

• locate an authenticated federal-court exhibit copy;

• or formally mark the source primary-capture BLOCKED and use the Ninth Circuit judicial description for claims that can be supported at that posture.

Never silently substitute a mirror.

6. The court testing menu is a first-party artifact

Court hosting establishes custody/public-trial provenance, not truth of the menu's implied technological capability.

7. 300 assays / >200 menu / 12 Edison assays are different denominators

Never render these as a numerical contradiction without labels.

• "developed" ≠ "published menu"

• "published menu" ≠ "run on Edison"

• "run at Theranos" ≠ "run on Theranos-developed device"

8. FDA K143236 is assay-specific

"FDA-cleared Theranos assay" is supportable.

"FDA approved Theranos" or "FDA validated the Theranos platform" is not supported by that record.

9. "Substantially equivalent" has a regulatory meaning

Do not paraphrase a 510(k) SE decision as proof of universal clinical superiority or correctness.

10. CMS "immediate jeopardy" has a regulatory meaning

Preserve the CLIA definition/context. It is not shorthand for:

• every patient was harmed;

• every test was wrong;

• criminal intent.

11. Sentencing press releases mix procedural facts with government narrative

Use the sentence/judgment as adjudicative. Treat explanatory descriptions of evidence as government characterization unless separately grounded in opinion/transcript/exhibit.

12. Ninth Circuit amended opinion is the current edition

The Feb. 24, 2025 opinion and Dec. 22, 2025 amended opinion are different artifacts. Claims should bind to the intended edition.

13. Court-staff summary is not the opinion

The Ninth Circuit PDF explicitly says its summary is not part of the court's opinion. For high-value claims, anchor to the opinion body.

14. Balwani's certiorari petition is pending as of this dossier date

As of August 9, 2026, Supreme Court No. 25-1330 is distributed for the Sept. 28, 2026 conference.

Do not say:

• Supreme Court affirmed;

• certiorari denied;

• appellate review is fully over.

This status is time-sensitive and must be recaptured at publication.

15. Current FDA database pages have current "last updated" metadata

A modern capture of a database entry is a 2026 observation of a record about a 2015 decision. The decision_date and observed_at must not be conflated.

16. Arizona settlement ≠ criminal merits finding

A consent judgment/restitution outcome has its own posture. Acquire the signed judgment before relying on exact admissions or factual stipulations.

17. Holmes trial evidence cannot be copied wholesale onto Balwani, and vice versa

Separate trials had overlapping but non-identical evidentiary records.

18. Patient harm is its own vertical

If a future Theranos page wants to assert specific medical harm:

• identify patient;

• exact test;

• collection method;

• device/method;

• result;

• comparison/confirmatory result;

• clinical consequence;

• expert/regulatory posture.

Do not infer individual harm from scandal-level evidence.

K. THERANOS CAPTURE DISPATCH SHAPE

For THERANOS-CAP1, acquire in this order:

1. TH-S09 current Ninth Circuit amended opinion

2. prior Feb. 24, 2025 Ninth Circuit opinion for source-edition comparison

3. TH-S05 Holmes verdict source

4. TH-S06 Balwani verdict source

5. resolve/capture district-court verdict forms and judgments for both defendants

6. TH-S01 SEC Holmes/Theranos complaint

7. TH-S02 SEC settlement announcement

8. TH-S03 SEC Balwani complaint

9. TH-S13 Theranos Testing Menu exact PDF

10. TH-S15 FDA K143236 database record and linked FDA decision-summary PDF

11. TH-S16 FDA/CLIA waived record

12. locate authentic TH-S11 CMS Jan. 25, 2016 PDF

13. locate authentic TH-S12 Mar. 18 / Jul. 7 CMS sanction records

14. exact operative Third Superseding Indictment

15. TH-S07 / TH-S08 sentencing materials

16. TH-S17 Arizona AG summary + signed consent judgment if resolvable

17. TH-S10 Supreme Court docket as a fresh time-sensitive observation

18. TH-S14 financial spreadsheet only if financial-measurement claims remain in first demo

CAP1 output remains intentionally boring:

• requested locator;

• final locator;

• HTTP status;

• media type;

• exact bytes/digest;

• capture observation;

• source-owned dates;

• case/docket identifiers;

• child-document relationships;

• extraction/passages available;

• table/image/spreadsheet anchoring needs;

• captured / refused / failed;

• no standing;

• no article prose.

L. PROVISIONAL THERANOS THESIS FOR REVIEW

Theranos should not be demoed as:

"Counterpedia proves Theranos was a fraud."

That is too easy and throws away the real value.

The stronger thesis is:

A scandal can be broadly settled in public memory while the record still requires exact verbs: alleged, settled, neither admitted nor denied, found deficient, charged, convicted, acquitted, dismissed, hung, sentenced, affirmed, and still under further review.

And the technology record has the same structure:

A narrow assay can receive genuine FDA clearance while broad platform claims remain unsupported or fraudulent. A menu can be real while the implication that one proprietary machine ran the whole menu is false.

Theranos therefore tests:

adjudication vs allegation

• settlement vs admission

• procedural disposition vs factual finding

• defendant-specific verdicts

• regulatory finding vs criminal guilt

• device/assay/menu denominator discipline

• source-edition drift

• time-sensitive appellate posture

The critical Counterpedia reveal is:

Holmes's patient-fraud acquittals do not erase the patient-testing record, and the patient-testing record does not permit us to rewrite her acquittals into convictions.

That is not rhetorical nuance. It is graph integrity.